Voyager Q3 Loss Narrows to $24.7M; $132.1M Cash Funds Operations Into Q2 2028
VYGR is trading near its 52-week low of $1.675 (0.9% above the low) on elevated volume (1.9× avg).
Summary
Voyager narrowed its Q3 2026 net loss to $24.7 million and held $132.1 million in cash and securities, enough to fund operations into the second quarter of 2028. Collaboration revenue fell to $4.0 million from $13.4 million a year earlier.
Key Events · Earnings and Guidance · VYGR
-
Q3 Loss Narrows on Cost Cuts
Net loss was $24.7 million versus $27.9 million in Q3 2025; R&D fell to $24.4 million from $35.9 million and G&A to $6.1 million from $8.1 million.
-
Cash Runway Into Q2 2028
Cash, cash equivalents and marketable securities totaled $132.1 million at September 30, 2026, down from $191.0 million at December 31, 2025; management projects funding into the second quarter of 2028.
-
Collaboration Revenue Declines
Revenue fell to $4.0 million from $13.4 million in Q3 2025 and to $9.8 million from $25.0 million for the nine months, driven by lower Neurocrine revenue recognition.
-
ATM Drip-Feeds $8.7M
Sold 2,236,872 shares under the $100.0 million ATM Facility at a weighted-average price of $4.00 for net proceeds of $8.7 million; $91.0 million remains available.
Analysis · VYGR · Life Sciences
Cost control is the story here: Voyager's quarterly loss narrowed to $24.7 million from $27.9 million a year ago, helped by restructuring and program prioritization that cut R&D to $24.4 million from $35.9 million. The company ended September with $132.1 million in cash and securities, down from $191.0 million at year-end, and says that funds operations into the second quarter of 2028 — roughly two and a half years of runway, which removes near-term financing pressure for a stock trading near its 52-week low. Collaboration revenue fell to $4.0 million from $13.4 million, so the story is cost control and runway rather than top-line growth. The next hard data point is initial tau PET efficacy data from the VY7523 Phase 1 MAD trial, expected in the fourth quarter of 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYGR was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106M. The 52-week trading range was $1.68 to $5.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.